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According to the second deﬁnition it was respectively,
43,63% and 25,64%. Cost of the doctors’ consultations
in the perindopril group was lower by 16,52% than in
the enalapril group, which represents a saving of €19,29
per patient per year. Indirect costs reduction in the
perindopril group amounted to €131,26 per patient per
year which means -54,06%. Total cost in the perindopril
group, was lower by €55,44 per patient per year than in
the enalapril group. Calculation of the cost-effectiveness
ratios according to the ﬁrst deﬁnition (Wp = 1020; WE =
1439) and the second deﬁnition (Wp = 1226; WE = 2303)
revealed the treatment with perindopril as a more cost-
effective than enalapril. CONCLUSION: The results of
the analysis revealed signiﬁcant cost reductions and better
blood pressure control in the perindopril group as com-
pared to the enalapril group. The savings in the perindo-
pril group resulted from the reduction of the physicians’




MANAGEMENT IN TWO MODELS OF CARE
You JH, Lai MW, Chan EM, Cheng G
The Chinese University of Hong Kong, Hong Kong, China
OBJECTIVES: Two models of ambulatory oral anticoag-
ulation management have been adopted in a teaching hos-
pital in Hong Kong, namely the anticoagulation clinic
(AC) and routine medical care (RMC). The objective of
this study was to compare the cost and outcomes of war-
farin therapy management at AC and RMC from the per-
spective of a public health organization. METHODS:
A retrospective observational study was performed by
reviewing the medical records of outpatients who were
initiated on warfarin from January 1, 1999 to June 30,
2001 in a teaching hospital. Effectiveness was assessed by
percentage of patient-time spent in target INR range and
the incidence of thromboembolic events (TE). Safety was
assessed by incidence of hemorrhage and warfarin over-
dose (INR > 5). Direct medical cost associated with the
management of warfarin therapy and anticoagulation
complications was also evaluated. The incidences were
expressed as percentage per patient-year. RESULTS:
Forty-one patients (71 patient-years) and 476 patients
(409 patient-years) were started on warfarin in AC and
RMC, respectively, during the study period. Patients
managed by AC spent signiﬁcantly more time in target
INR range than those in RMC group (58% vs. 44%; p =
0.002) and had a lower incidence of INR > 5 (1.4% vs.
7.1%; p = 0.068). The AC group patients had a lower
rate of TE (4.2% vs. 7.6%; p = 0.443) and major to fatal
bleeding (0% vs. 9.5%; p = 0.01). The total direct medical
cost of AC was lower than that of RMC by 44%
(HKD4838 vs. HKD8595 per patient year; 1USD =
7.8HKD). CONCLUSION: The establishment of the AC
improved the effectiveness, safety, and decreased the
direct medical cost of oral anticoagulation therapy.
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OBJECTIVES: Cardiovascular diseases (CVD) are one of
the leading causes of morbidity and mortality in Italy.
Atorvastatin treatment has shown to be effective in con-
trolling cholesterol levels in hyperlipidemic subjects.
Scope of this analysis is to evaluate the pharmacoeco-
nomic proﬁle of Atorvastatin compared to other statins
in subjects with a global CVD yearly risk >2%.
METHODS: Alternatives: Atorvastatin (low dose) vs
other statins (low dose) on the Italian market (weighted
with the current market shares, Atorvastatin excluded).
Perspective: National Health Service (NHS). Technique:
cost-effectiveness analysis on 2 hypothetical cohorts of
1000 subjects in primary prevention, with a global CVD
yearly risk >2%; an incremental cost per life year gained
(LYG) has been calculated. Time: 5 years. Costs: drugs
and direct medical costs quantiﬁed by using NHS tariffs
expressed in Euro 2002. Effects: the effects of different
statins in controlling cholesterol levels, as measured with
the CURVES study (Jones P et al, Am J Cardiol 1998),
have been used to model mortality and morbidity from
CVD with the Framingham Risk Equations (Anderson
KM et al, Am Heart J 1990). RESULTS: In the Atorvas-
tatin group the cost of drug therapy and events was
€2.213.415 for 58 LYG, resulting in an incremental cost
per LYG of €38.178. With other statins the cost of drug
therapy and events was €2.569.512 for 49 LYG, result-
ing in an incremental cost per LYG of €52.933. The 
differences always favoured the subjects treated with
Atorvastatin. CONCLUSIONS: This economic evalua-
tion shows that Atorvastatin is dominant over the treat-
ment with other statins as currently prescribed, as it
allows a higher number of LYG and is less costly.
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OBJECTIVE: A recent randomized clinical trial demon-
strated that improvement in moderate to severe conges-
tive heart failure (CHF) with treatment for anemia. To
estimate the health economic implications of treating
anemia with subcutaneous erythropoietin and intra-
venous iron in patients with moderate to severe CHF.
METHODS: A Markov model of CHF was developed
using New York Heart Association (NYHA) classes as the
main states and the effects of anemia treatment on these.
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At the start, all patients are in class III or IV. The risks of
hospitalization, death and change in class are considered
on a monthly basis, depending on current NYHA class.
Hospitalizations and deaths are accumulated over 1 year
and survival is quality-adjusted according to class. Direct
medical costs of treatment, hospitalizations and deaths
from a third-party payor perspective are reported in 2002
Canadian dollars. RESULTS: In 1,000 patients (class III:
19%, IV: 81%), treating anemia improves severity (class
I: 4%, II: 61%, III: 19%, IV: 15%), whereas without
treatment there is deterioration: class III: 13%, IV: 87%.
Over one year, this results in avoidance of 108 hospital-
izations and 24 deaths, increased survival of 142 months
(a 51% increase in quality-adjusted life-months) and
savings of over $1.2 million. Treatment with erythropoi-
etin and intravenous iron will cost on average $3,680 per
year per patient. Thus, improving one patient from class
III or IV to I or II costs $4,380, a cost-effectiveness ratio
of $13,620 per QALY. CONCLUSION: The enormous
improvement in NYHA class with anemia treatment in
CHF would result in very cost-effective improvement in
quality of life and in survival.
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OBJECTIVE: It is well recognized that major
atherothrombotic events are associated with substantial
resource use, translating to signiﬁcant economic burden.
The impact of peripheral arterial disease (PAD) is less
clear. In this study, we described the resource use associ-
ated with a diagnosis of PAD relative to stroke and
myocardial infarction (MI). METHODS: Hospitalization
records were examined for 16,440 patients diagnosed
with PAD in Saskatchewan, Canada between 1985–1995,
and compared to records for patients suffering a stroke
(18,704) or MI (15,590) between 1990–1995; all fol-
lowed to December 2000. Hospitalization rates for any
cause, cardiovascular disease (CVD) and bleeding events
in the ﬁve years following diagnosis were estimated and
compared across diagnoses. RESULTS: Approximately
half of PAD (45%) and stroke (52%) patients and 36%
of MI patients are female. Mean age ranged from 67–70
years of age across groups. Overall, between 73% and
86% of patients were hospitalized at least once, with the
PAD group experiencing the greatest frequency (mean =
5.2, sd = 5.0) compared to MI (4.8, 4.5) and stroke (3.9,
3.9). In year one, rates of all-cause hospitalization were
0.86, 1.08, and 0.85 per patient year (PY) for PAD, MI,
and stroke, respectively; for CVD hospitalization they
were: 0.17, 0.35, and 0.21 per PY. In year two, the rate
of all-cause hospitalization was highest for PAD patients
(0.62 vs. 0.58 per PY for stroke and MI) and remained
above or equal to that for MI and stroke in years three,
four, and ﬁve. Similar patterns were observed for CVD
hospitalizations, while rates for bleed-related hospitaliza-
tions were essentially equivalent. CONCLUSIONS: A
diagnosis of PAD is associated with substantial resource
utilization comparable to that observed among patients
suffering a major atherothrombotic event. The economic
implications of a PAD diagnosis ought to be taken as seri-
ously as that of MI and a stroke.
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OBJECTIVE: To compare ﬁve choices to initiate antihy-
pertensive pharmacotherapy as a function of persistence
with treatment and drugs cost. METHODS: An admin-
istrative database, held by the Local Health Unit of
Ravenna, recording pharmacy claims was used to
perform an observational study of patients receiving anti-
hypertensive drugs for the ﬁrst time. All new users, 20
years-old or over, receiving a prescription for amlodipine,
atenolol, fosinopril, indapamide or losartan between
January 1st, 1997 and December 31st, 1997 were
enrolled. The follow up period lasted 365 days. A
bayesian cost-effectiveness analysis based on Markov
Chain Monte Carlo simulations was performed. Persis-
tence with treatment (a duration of therapy on any anti-
hypertensive drug more than 273 days) at a correct
dosage (within the therapeutic range recommended by the
JNC VI) was assumed as a proxy to deﬁne effective ther-
apies. Drugs cost was evaluated at NHS purchase prices.
RESULTS: A total of 4614 subjects was enrolled (22.8%
on amlodipine, 44.0% on atenolol, 18.8% on fosinopril,
6.7% on indapamide, and 7.8% on losartan). The annual
average cost of treatment ranged between €44.27 
(95% CI 38.18–52.06) for those started on atenolol to 
€175.65 (95% CI 150.37–205.10) for those started on
losartan. The average probability of an effective antihy-
pertensive treatment ranged from 8.40% for those initi-
ated on fosinopril to 18.36% for those initiated on
losartan. As a consequence, the choice to initiate antihy-
pertensive treatment on losartan displayed a probability
of being more cost-effective equal to 0.99 compared to
fosinopril, 0.94 to amlodipine, 0.84 to indapamide, and
0.75 to atenolol. CONCLUSION: The low reproducibil-
ity of ﬁndings from experimental studies to clinical prac-
tice should encourage health care providers to account
and assess both resources and associated outcomes in a
“real world” setting: the availability of a linkage between
these variables could affect the cost-effectiveness of
selected choices.
